Following the positive single-dose results from the phase I study evaluating SOL-116, Lipum is now presenting additional promising data. The multiple-dose part of the study is now complete, and the safety profile continues to look good. Recruitment is currently ongoing for the third and final part, which involves rheumatoid arthritis patients.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/lipums-ceo-comments-on-multiple-dose-results-in-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/lipum-ab/r/biostock-lipum-s-ceo-comments-on-multiple-dose-results-in-phase-i,c4004088

(c) 2024 Cision. All rights reserved., source Press Releases - English